Home

STEVEN M PAUL

CIK 1237564 · CSO and President of R&D · last filed 2026-06-10

STEVEN M PAUL is a CSO and President of R&D who has filed 102 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for RAPP, was dated Jun 10, 2026. Across all open-market trades the lifetime net is −$76.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $70.9M across reported positions. 18 SEC filings were submitted jointly with ALNYLAM PHARMACEUTICALS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$70.89M

Companies

8

Total Filings

102

Lifetime Open-Market Net

-$76.46M

Filer Profile

Reported Address
RAPPORT THERAPEUTICS, INC.
1325 BOYLSTON STREET, SUITE 401
BOSTON, MA 02215
Related Filers
ALNYLAM PHARMACEUTICALS, INC. — 18 joint filings, latest 2022-04-05
LILLY & Co ELI — 9 joint filings, latest 2010-02-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
RAPP Director 28,284 $43.62 $1.23M $1.03M 3 2026-06-10
SPTX Director 863,031 $23.34 $20.14M $0 1 2026-05-04
Karuna Therapeutics, Inc. (KRTX) Delisted CSO and President of R&D 0 $329.83 $0 -$29.76M 12 2024-03-18
Sage Therapeutics, Inc. (SAGE) Delisted Director 303,377 $8.68 $2.63M -$37.05M 29 2024-01-04
ALNY Director 10,799 $248.68 $2.69M -$8.47M 16 2022-04-05
VYGR Chief Executive Officer 872,351 $3.19 $2.78M $140.7K 7 2021-06-04
SIGMA ALDRICH CORP (SIAL) Delisted Director 0 — — $0 19 2015-11-19
LLY EVP, Science and Technology 39,476 $1115.70 $44.04M -$2.35M 15 2010-02-03

Recent Filings

102 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-10 RAPP Grant (A) — $0 EDGAR
2026-05-04 SPTX Mixed +67,031 $0 EDGAR
2025-09-15 RAPP Buy (P) +41,666 $1.03M EDGAR
2025-06-18 RAPP Grant (A) — $0 EDGAR
2024-03-18 Karuna Therapeutics, Inc. (KRTX) Delisted Disp (D) −150,963 -$49.82M EDGAR
2024-03-04 Karuna Therapeutics, Inc. (KRTX) Delisted Mixed +47,378 $14.93M EDGAR
2024-02-26 Karuna Therapeutics, Inc. (KRTX) Delisted Exer (M) +31,518 $599.7K EDGAR
2024-02-12 Karuna Therapeutics, Inc. (KRTX) Delisted Tax (F) −804 -$255.0K EDGAR
2024-01-04 Sage Therapeutics, Inc. (SAGE) Delisted Grant (A) — $0 EDGAR
2023-06-16 Sage Therapeutics, Inc. (SAGE) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 102
Page 1 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.